Lee M J, Mueller P R, Dawson S L, Gazelle S G, Hahn P F, Goldberg M A, Boland G W
Department of Radiology, Massachusetts General Hospital, Boston 02114.
AJR Am J Roentgenol. 1995 Jan;164(1):215-20. doi: 10.2214/ajr.164.1.7998542.
Percutaneous injection of ethanol for treatment of hepatic tumors was first described by Sugiura et al. [1] in 1983. To date, reported experience with the procedure has focused mainly on therapy of hepatocellular carcinoma (HCC) [2-15], with little information available regarding its use in treating metastatic liver lesions [16]. Interest in this technique has grown recently as a possible means of treating patients with metastatic liver disease. The purpose of this perspective is to review the indications, mechanism of action, technique, complications, and efficacy of percutaneous ethanol injection for liver tumor treatment.
经皮注射乙醇治疗肝肿瘤最早由杉浦等人于1983年报道[1]。迄今为止，有关该方法的报道经验主要集中在肝细胞癌（HCC）的治疗上[2 - 15]，而关于其在治疗肝转移瘤方面的应用信息很少[16]。最近，作为治疗肝转移疾病患者的一种可能方法，人们对该技术的兴趣有所增加。本文的目的是综述经皮乙醇注射治疗肝肿瘤的适应证、作用机制、技术、并发症及疗效。
